NCT00077428View on ClinicalTrials.gov

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2007

Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Salivary Gland CancerSalivary Gland Adenoid Cystic CarcinomaStage III Adenoid Cystic Carcinoma of the Oral CavityStage III Salivary Gland CancerStage IV Adenoid Cystic Carcinoma of the Oral CavityStage IV Salivary Gland Cancer
Interventions
DRUG

bortezomib

Given IV

DRUG

doxorubicin hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
collaborator

SWOG Cancer Research Network

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00077428 - Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck | Biotech Hunter | Biotech Hunter